You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pembrolizumab

Showing 51 - 75 of 2,041
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Breast Cancer Trial (Sacituzumab govitecan, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Sacituzumab govitecan
  • Pembrolizumab
  • (no location specified)
Oct 5, 2023

Renal Cell Carcinoma Trial (Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy,

Not yet recruiting
  • Renal Cell Carcinoma
  • Neoadjuvant Lenvatinib
  • +3 more
  • (no location specified)
Dec 23, 2022

Colorectal Cancer Trial (Pembrolizumab)

Recruiting
  • Colorectal Cancer
  • Pembrolizumab
  • Amsterdam, Netherlands
    Netherlands Cancer Institute
Jan 3, 2023

NSCLC, HNSCC, Melanoma Trial (CJRB-101, Pembrolizumab injection)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Jun 1, 2023

Renal Cancer, Kidney Cancer, Renal Cell Carcinoma Trial in Aurora (Axitinib, Pembrolizumab)

Not yet recruiting
  • Renal Cancer
  • +3 more
  • Aurora, Colorado
    University of Colorado Cancer Center
Jul 24, 2023

Oligometastatic Squamous Cell Carcinoma of the Head and Neck Trial (Pembrolizumab, stereotattic ablation radiotherapy (SABR))

Not yet recruiting
  • Oligometastatic Squamous Cell Carcinoma of the Head and Neck
  • Pembrolizumab
  • stereotattic ablation radiotherapy (SABR)
  • (no location specified)
Apr 14, 2023

Colorectal Cancer Trial in Koege (Influenza vaccine, Pembrolizumab)

Not yet recruiting
  • Colorectal Cancer
  • Influenza vaccine
  • Pembrolizumab
  • Koege, Zealand, Denmark
    Center for Surgical Science, Department of Surgery, Zealand Univ
Jun 9, 2023

Advanced Solid Tumor, Metastatic Solid Tumor Trial in Nashville, Dallas, Fairfax (JZP898, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Nashville, Tennessee
  • +2 more
Oct 26, 2023

Hepatocellular Carcinoma Trial (Pembrolizumab)

Active, not recruiting
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • (no location specified)
Dec 15, 2022

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 26, 2022

Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer Trial (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Recurrent Vulvar Cancer
  • +3 more
  • (no location specified)
Jun 12, 2023

Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab vedotin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 20, 2023

Locally Advanced Esophageal and Gastric Cancers (EGC) Trial in Durham (Pembrolizumab)

Active, not recruiting
  • Locally Advanced Esophageal and Gastric Cancers (EGC)
  • Pembrolizumab
  • Durham, North Carolina
    Duke Cancer Center
Dec 7, 2022

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Pembrolizumab
  • +3 more
  • Boston, Massachusetts
  • +1 more
Feb 11, 2023

Advanced or Metastatic Solid Tumors Trial (PRTH-101, Pembrolizumab)

Not yet recruiting
  • Advanced or Metastatic Solid Tumors
  • PRTH-101
  • Pembrolizumab
  • (no location specified)
Feb 27, 2023

Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

Not yet recruiting
  • Advanced Cancer
  • Non Small Cell Lung Cancer
  • (no location specified)
Mar 28, 2023

Triple-negative Breast Cancer Trial (Pembrolizumab 25 mg/ml, Paclitaxel injection)

Not yet recruiting
  • Triple-negative Breast Cancer
  • Pembrolizumab 25 mg/ml
  • Paclitaxel injection
  • (no location specified)
Oct 11, 2023

Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)

Not yet recruiting
  • Metastatic Triple-Negative Breast Cancer
  • Charlotte, North Carolina
    Levine Cancer Institute
Aug 31, 2023

Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Fungoides Mycosis Sezary Syndrome
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Jul 13, 2023

Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue Trial in Warsaw (Pembrolizumab, Eftilagimod alpha)

Recruiting
  • Neoadjuvant
  • +3 more
  • Pembrolizumab, Eftilagimod alpha
  • Warsaw, Poland
    Maria Sklodowska-Curie National Research Institute of Oncology
Nov 7, 2023

HPV-Related Squamous Cell Carcinoma, HNSCC Trial in London (VB10.16, Pembrolizumab)

Not yet recruiting
  • HPV-Related Squamous Cell Carcinoma
  • HNSCC
  • VB10.16
  • Pembrolizumab
  • London, United Kingdom
    East and North Hertfordshire NHS Trust Mount Vernon Hospital
Aug 24, 2023

Oropharyngeal Squamous Cell Carcinoma (SCC) Trial run by the National Cancer Institute (NCI) (PRGN-2009, Pembrolizumab)

Not yet recruiting
  • Oropharyngeal Squamous Cell Carcinoma (SCC)
  • PRGN-2009
  • Pembrolizumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 22, 2023

Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)

Not yet recruiting
  • Ovarian Cancer
  • Pembrolizumab
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Metastatic Non-squamous Lung Cancer Trial in Villejuif (Pembrolizumab 200 mg Q6W, Pemetrexed 500 mg/m^2 Q3W, Pembrolizumab 200

Not yet recruiting
  • Metastatic Non-squamous Lung Cancer
  • Pembrolizumab 200 mg Q6W
  • +2 more
  • Villejuif, Val-de-Marne, France
    Institut Gustave Roussy
Jan 11, 2023